Announcement Summary

Entity name

CARDIEX LIMITED

Announcement Type

New announcement

Date of this announcement

18/12/2024

The Proposed issue is:
A placement or other type of issue

Total number of +securities proposed to be issued for a placement or other type of issue

ASX +security code	+Security description	Maximum Number of +securities to be issued
CDX	ORDINARY FULLY PAID	36,111,112
CDXOA	OPTION EXPIRING 30-NOV-2025	36,111,112

Proposed +issue date

24/12/2024

Refer to next page for full details of the announcement

Part 1 - Entity and announcement details

1.1 Name of +Entity

CARDIEX LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.
If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type	**Registration Number**
ABN	81113252234

1.3 ASX issuer code

CDX

1.4 The announcement is
New announcement

1.5 Date of this announcement

18/12/2024

1.6 The Proposed issue is:
A placement or other type of issue

Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?
Yes

7A.1a Conditions

Approval/Condition	Date for determination	Is the date estimated or actual?	** Approval received/condition met?
+Security holder approval	28/11/2025	Estimated	

Comments

Directors participation in the Placement is subject to shareholder approval to be sought at the earlier of the 2025 Annual General Meeting or an extraordinary general meeting convened by the Company prior.

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?
Existing class

Will the proposed issue of this +security include an offer of attaching +securities?
Yes

Details of +securities proposed to be issued

ASX +security code and description

CDX : ORDINARY FULLY PAID

Number of +securities proposed to be issued

36,111,112

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?
Yes

In what currency is the cash consideration being paid?

AUD - Australian Dollar

What is the issue price per +security?

AUD 0.09000

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

Attaching +Security

Is the proposed attaching security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional +securities in a class that is already quoted or recorded by ASX)?
Existing class

Attaching +Security - Existing class (additional +securities in a class that is already quoted or recorded by ASX)

Details of attaching +securities proposed to be issued

ASX +security code and description

CDXOA : OPTION EXPIRING 30-NOV-2025

Number of +securities proposed to be issued

36,111,112

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?
No

Please describe the consideration being provided for the +securities

Securities issued as free attaching options with Placement being conducted. Placements participants receive an Option on a 1:1 basis. The attaching Options for the Director Placement is subject to shareholder approval to be sought at the earlier of the 2025 Annual General Meeting or an extraordinary general meeting convened by the Company prior.

Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities

0.000001

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?
Yes

Part 7C - Timetable

7C.1 Proposed +issue date

24/12/2024

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?
No

7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?
Yes

7D.1b (i) How many +securities are proposed to be issued without security holder approval using the entity's 15% placement capacity under listing rule 7.1?

11,963,685 Fully Paid Ordinary Shares and 32,500,000 free attaching Quoted Options

7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?

Yes

7D.1c (i) How many +securities are proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A?

20,536,315 Fully Paid Ordinary Shares

7D.1c (ii) Please explain why the entity has chosen to do a placement rather than a +pro rata issue or an offer under a +security purchase plan in which existing ordinary +security holders would have been eligible to participate

The Company decided to undertake a Placement as the most time and cost effective method to raise the amount of capital required to undertake its planned operations.

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?

Yes

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?

No

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?

No

Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue?

Yes

7E.1a Who is the lead manager/broker?

Joint Lead Managers Blackpeak Capital Pty Ltd and Stralis Capital Partners

7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

The Joint Lead Managers are entitled to: (a) 3% of the Gross Proceeds under the Placement (Management Fee), and (b) 3% of the Gross Proceeds under the Placement (Selling Fee). Gross Proceeds refers to the total amount raised under the Placement.

7E.2 Is the proposed issue to be underwritten?

No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

Fees associated with preparing the Options Prospectus to cleanse the shares proposed to be issued and to offer the free attaching Quoted Options.

Part 7F - Further Information

7F.01 The purpose(s) for which the entity is issuing the securities

Device manufacturing (inc. the build-up of inventory), marketing and sales activities, and payments to suppliers and contractors, commercial expansion (inc. scaling up supply chain, order fulfilment etc), R&D, and general working capital purposes.

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?

No

7F.2 Any other information the entity wishes to provide about the proposed issue

As per the disclosures above, the issue of Director Placement shares (inc. the attached Quoted Options) are subject to shareholder approval to be sought at the earlier of the 2025 Annual General Meeting or an extraordinary general meeting convened by the Company prior. 3,611,112 fully paid ordinary shares and 3,611,112 free attaching quoted options to be issued to the Cardiex Directors will be subject to shareholder approval and therefore not issued under the Company¿s placement capacity

7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:
The publication of a +disclosure document or +PDS involving the same class of securities as the +securities proposed to be issued that meets the requirements of section 708A(11) or 1012DA(11)